Current Studies

Clinical trials are vital in developing and evaluating new treatments for children with rheumatologic diseases.

Studies currently being conducted by the PRCSG include:

Title Sponsor
A Long-term, Multicenter, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of Humira (adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - STRIVE AbbVie
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis Bristol-Myers Squibb
A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs Bristol-Myers Squibb
 A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy Janssen Research & Development, LLC
 A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus GlaxoSmithKline
A Phase I pharmacokinectic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) Hoffman-La Roche
A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Hoffman-La Roche / Genentech
A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis, With an Open-Label Extension to Examine the Long Term Use of Tocilizumab Hoffman- La Roche
A study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients with Systemic Juvenile Idiopathic Arthritis Hoffman- La Roche
A study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients with Polyarticular-course Juvenile Idiopathic Arthritis Hoffman-La Roche
A study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab Hoffman-La Roche
 Long-Term extension study to evaluate the safety and efficacy of subcutaneous tocilizumab in patient with polyarticular-course and systemic juvenile idiopathic arthritis Hoffman-La Roche
An open label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation Novartis Pharmaceuticals
 A Long-term, Open-label Follow-up Study Of Cp-690,550 For Treatment Of Juvenile Idiopathic Arthritis (Jia) Pfizer
 Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects Pfizer
Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) UBC, Inc